




Genmab A/S
Investor Relations Department
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

[Visit IR website](#) 
[Sign-up for email alerts](#) 

OMX: GEN.OMX

| | |
|---------------|---|
| Last Trade: | 1039.00 |
| Trade Time: | 11:57 AM CET Dec 18, 2017 |
| Change: | 7.00  (0.678%) |
| Day Range | 1030.00 - 1065.00 |
| 52-Week Range | 1015.00 - 1489.00 |
| Volume | 165,280 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Genmab A/S is listed on the NASDAQ Copenhagen A/S under the ticker symbol GEN and is traded as part of the OMXC20. Genmab is committed to proactive interaction with our shareholders and to provide reliable and transparent information about our business, development programs and results in an open and timely manner. In this area you can find information about Genmab's latest share price, our recent news flow and other relevant shareholder information related to our listing on Nasdaq.

... [\(more\)](#)

Press Releases [\[View all \]](#)

Dec 15, 2017

[Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab](#)

Dec 11, 2017

[Genmab's 2017 R&D Update](#)

Dec 4, 2017

[Genmab to Hold 2017 R&D Update](#)

Nov 29, 2017

[Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance](#)

Nov 21, 2017

[Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma](#)

Upcoming Events [\[View all \]](#)

Dec 31, 2017

[Financial calendar year end](#)

Jan 8–11, 2018

[36th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US](#)